Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto

a prostacyclin and receptor technology, applied in the preparation of urea derivatives, cardiovascular disorders, drug compositions, etc., can solve the problems of unable to register for the treatment of pah in europe, complicated intravenous treatment, and patients at risk of potentially fatal rebound pulmonary hypertension

Inactive Publication Date: 2013-08-22
ARENA PHARMA
View PDF0 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

These cyclohexane derivatives effectively treat PAH and related conditions by providing a stable, orally-active modulation of the PGI2 receptor, reducing the risks associated with traditional treatments and improving management of PAH and other diseases.

Problems solved by technology

Beraprost is an orally-active analog of prostacyclin approved for the treatment of PAH in Japan, but it has failed registration for the treatment of PAH in Europe and in the US.
Due to the short half-life of prostacyclin, intravenous treatment is complicated by the need for a continuous infusion.
Patients are at risk for potentially fatal rebound pulmonary hypertension if the infusion is abruptly disrupted, as well as significant risk of catheter-related complications including sepsis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
  • Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
  • Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto

Examples

Experimental program
Comparison scheme
Effect test

example 1

Syntheses of Compounds of the Present Invention

[1104]Illustrated syntheses for compounds of the present invention are shown in FIGS. 1 through 6 where the symbols have the same definitions as used throughout this disclosure.

[1105]The compounds of the invention and their syntheses are further illustrated by the following examples. The following examples are provided to further define the invention without, however, limiting the invention to the particulars of these examples. The compounds described herein, supra and infra, are named according to the CS ChemDraw Ultra Version 7.0.1, AutoNom version 2.2, or CS ChemDraw Ultra Version 9.0.7. In certain instances common names are used and it is understood that these common names would be recognized by those skilled in the art.

[1106]Chemistry:

[1107]Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker Avance-400 equipped with a QNP (Quad Nucleus Probe) or a BBI (Broad Band Inverse) and z-gradient. Chemical shifts are...

example 1.1

Preparation of tert-Butyl 2-(((1s,4s)-4-((Phenylcarbamoyloxy)methyl)cyclo-hexyl) methoxy)acetate

Step A: Preparation of (1s,4s)-Diethyl Cyclohexane-1,4-dicarboxylate

[1109]To a solution of (1s,4s)-cyclohexane-1,4-dicarboxylic acid (25 g, 145 mmol) in ethanol (150 mL) was added concentrated H2SO4 (98%, 1 mL). The reaction was heated to reflux for 16 h, cooled to room temperature and concentrated. The residue was extracted with EtOAc and saturated NaHCO3, washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated to provide the title compound as colorless oil (30.5 g). 1H NMR (400 MHz, CDCl3) δ ppm 1.25 (t, J=7.14 Hz, 6H), 1.62-1.75 (m, 4H), 1.84-1.97 (m, 4H), 2.40-2.50 (m, 2H), 4.13 (q, J=7.12 Hz, 4H).

Step B: Preparation of (1s,4s)-Cyclohexane-1,4-diyldimethanol

[1110]To a solution of (1s,4s)-diethyl cyclohexane-1,4-dicarboxylate (13.0 g, 56.9 mmol) in THF (500 mL) was added lithium aluminum hydride (4.54 g, 120 mmol) in portions at 0° C. The mixture was stirred at...

example 1.2

Preparation of 2-(((1s,4s)-4-(((4-Methoxyphenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic Acid (Compound 24)

[1113]To a solution of tert-butyl 2-(((1s,4s)-4-((phenylcarbamoyloxy)methypeyclohexyl)methoxy)acetate (0.1 g, 0.265 mmol) in dioxane (2 mL) were added 1-iodo-4-methoxybenzene (0.062 g, 0.265 mmol), (1R,2R)-cyclohexane-1,2-diamine (0.030 g, 0.265 mmol), CuI (0.02 g, 0.158 mmol), and K3PO4 (0.1 g, 0.471 mmol) at room temperature. The reaction mixture was sealed in a reaction vial and heated to 150° C. under microwave irradiation for 4 h. The mixture was filtered and the filtrate was concentrated. The residue was treated with HCl (4.0 N in dioxane, 5 mL) for 16 h. The resulting mixture was concentrated and purified by preparative HPLC. LCMS m / z=428.2 [M+H]+; 1H NMR (400 MHz, DMSO-d6) δ ppm 1.34-1.56 (m, 8H), 1.70-1.88 (m, 2H), 3.31 (s, 3H), 3.39 (d, J=7.07 Hz, 2H), 4.00 (d, J=7.20 Hz, 2H), 4.11 (s, 2H), 6.94-7.01 (m, 2H), 7.23-7.31 (m, 4H), 7.42-7.49 (m, 3H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease; and other diseases.

Description

FIELD OF THE INVENTION[0001]The present invention relates to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with: a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07C271/28C07C275/28C07D277/48C07D333/36C07C275/34C07D241/20C07C275/24C07D213/75
CPCC07B2200/07A61K31/27C07C271/12C07C271/28C07C275/24C07C275/28C07C275/30C07C275/34C07C309/15C07C2101/14C07D213/75C07D241/20C07D277/48C07D333/36C07B2200/13C07B53/00C07C2601/14A61P11/00A61P11/06A61P11/16A61P9/00A61P9/10A61P9/12A61K31/196A61K31/44A61K31/195A61K31/496A61P7/02A61P31/12A61P3/10A61P25/02A61P27/02A61P17/06A61P19/02A61P1/00A61P1/04A61P17/10A61P37/06A61K31/325A61K31/381A61K31/426A61K31/4402A61K31/4406A61K31/4965
Inventor TRAN, THUY-ANHCHEN, WEICHAOKRAMER, BRYAN A.SADEQUE, ABU J.M.SHIFRINA, ANNASHIN, YO NG-JUNVALLAR, PUREZAZOU, NING
Owner ARENA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com